The AGLYC project is about developing a new IVD test based on the quantification of specific protein modifications as a novel and disruptive approach to detect cardiac ischemia.
The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 826930 (Phase I) and No. 849047 (Phase II).
Production of AGLYC Reagents
Clinical Validation of AGLYC
Business Relevant Activities IP Protection
Regulatory Quality Management
Communication and Dissemination
A GlyCardial Diagnostics’ Project
Be the first to read
We are honoured to announce that our CEO Judit Cubedo has been selected as finalist for the EU Prize for Women Innovators 2020!
© Copyright 2019. All rights reserved